Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 225 of 267 entries
View as:

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant

Phase: N/A Priority: Normal
NCT ID: NCT06213818 Org: User:
Start: 03/14/24 End: 11/19/25 Due: 11/19/26

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

Phase: N/A Priority: Normal
NCT ID: NCT03361865 Org: User:
Start: 12/04/17 End: 08/04/20 Due: 08/04/21

Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02559492 Org: User:
Start: 11/30/15 End: 08/18/19 Due: 08/18/20

Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1

Phase: N/A Priority: Normal
NCT ID: NCT05219864 Org: User:
Start: 01/31/23 End: 09/22/24 Due: 09/22/25

Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)

Phase: N/A Priority: Normal
NCT ID: NCT02252159 Org: User:
Start: 07/31/14 End: 08/03/19 Due: 08/03/20

Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients

Phase: N/A Priority: Normal
NCT ID: NCT00393120 Org: User:
Start: 10/31/06 End: 09/30/07 Due: 09/30/08

Expanded Access Use of Itacitinib to Treat a Single Patient With STAT1 Gain of Function (GOF) Disease

Phase: N/A Priority: Normal
NCT ID: NCT05561985 Org: User:
Start: - End: - Due: -

A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT06309394 Org: User:
Start: 05/15/24 End: 06/04/24 Due: 06/04/25

A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550

Phase: N/A Priority: Normal
NCT ID: NCT05101369 Org: User:
Start: 01/21/22 End: 03/25/22 Due: 03/25/23

Expanded Access Use of INCB054329 to Treat a Single Patient With Metastatic Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03896815 Org: User:
Start: - End: - Due: -

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Phase: N/A Priority: Normal
NCT ID: NCT04551066 Org: User:
Start: 05/27/21 End: 11/25/24 Due: 11/25/25

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Phase: N/A Priority: Normal
NCT ID: NCT03144674 Org: User:
Start: 12/18/17 End: 05/29/24 Due: 05/29/25

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT03745638 Org: User:
Start: 12/20/18 End: 12/01/20 Due: 12/01/21

A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

Phase: N/A Priority: Normal
NCT ID: NCT05620836 Org: User:
Start: 02/22/23 End: 01/30/26 Due: 01/30/27

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

Phase: N/A Priority: Normal
NCT ID: NCT06113471 Org: User:
Start: 11/27/23 End: 05/17/27 Due: 05/17/28

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

Phase: N/A Priority: Normal
NCT ID: NCT05764161 Org: User:
Start: 06/12/23 End: 10/25/25 Due: 10/25/26

A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

Phase: N/A Priority: Normal
NCT ID: NCT06818812 Org: User:
Start: 03/27/25 End: 03/27/27 Due: 03/27/28

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Phase: N/A Priority: Normal
NCT ID: NCT04551053 Org: User:
Start: 05/26/21 End: 08/21/24 Due: 08/21/25

Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)

Phase: N/A Priority: Normal
NCT ID: NCT03039114 Org: User:
Start: 02/15/17 End: 03/30/21 Due: 03/30/22

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT07008118 Org: User:
Start: 07/30/25 End: 12/14/29 Due: 12/14/30

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

Phase: N/A Priority: Normal
NCT ID: NCT03123588 Org: User:
Start: 11/14/17 End: 08/03/20 Due: 08/03/21

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05836324 Org: User:
Start: 07/24/23 End: 01/13/27 Due: 01/13/28

INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs

Phase: N/A Priority: Normal
NCT ID: NCT00902486 Org: User:
Start: 05/31/09 End: 07/31/10 Due: 07/31/11

INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04580485 Org: User:
Start: 02/03/21 End: 01/22/24 Due: 01/22/25

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT02718300 Org: User:
Start: 02/08/17 End: 04/29/22 Due: 04/29/23